Want to see TSE:CRON full AI Analyst Report?
CRON Stock Chart & Stats
C$4.95
C$0.09(2.27%)
At close: 4:00 PM EDT
C$4.95
C$0.09(2.27%)
Day’s Range― - ―
52-Week RangeC$3.23 - C$4.99
Previous CloseN/A
Volume145.76K
Average Volume (3M)134.78K
Market Cap
C$1.68B
Enterprise ValueC$410.50
Total Cash (Recent Filing)C$797.02M
Total Debt (Recent Filing)C$1.29M
Price to Earnings (P/E)17.2
Beta1.21
Next Earnings
Nov 11, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding368,412,870
10 Day Avg. Volume116,850
30 Day Avg. Volume134,785
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)0.92
Price to Sales (P/S)6.74
P/FCF Ratio6.63K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$7.00Price Target Upside41.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.15
Revenue Forecast (FY)C$199.00M
Bulls Say, Bears Say
Bulls Say
Strong Revenue And EBITDA GrowthThe sharp expansion in revenue, gross profit, and adjusted EBITDA indicates stronger demand and improving operating leverage across the business. If sustained, this momentum can support reinvestment in brands and capacity while strengthening Cronos’s competitive position over the next several quarters.
Conservative Balance SheetExtremely low leverage gives Cronos substantial financial flexibility and reduces the burden of interest costs or refinancing needs. A conservatively financed balance sheet can help the company withstand cannabis-market volatility, fund growth initiatives, and pursue opportunities without relying heavily on external capital.
Brand And International ExpansionBrand growth well above the category, combined with rapid international expansion, demonstrates that Cronos is gaining share rather than merely benefiting from industry growth. Broader geographic traction and established product positions can create a more diversified and durable revenue base.
Bears Say
Profitability Remains InconsistentDespite improved operating results, the continued negative TTM net margin shows that the turnaround has not yet translated into consistently positive bottom-line earnings. The history of operating losses makes future profitability less certain and leaves results sensitive to execution, product mix, and cost discipline.
Gross Margin VolatilityMargin gains partly benefited from favorable growing conditions and a mix tilted toward higher-ASP markets and vapes. Because those factors can change, gross-profit performance may be uneven across quarters, making earnings quality less predictable and requiring sustained operational execution to preserve margins.
Israel Regulatory InvestigationThe investigation creates an ongoing regulatory risk in an important growth market, where Cronos Israel has delivered ten consecutive record quarters. Potential changes to import treatment or market access could affect competitive conditions, pricing, and the durability of the segment’s recent expansion.
Cronos Group News
CRON FAQ
What was Cronos Group’s price range in the past 12 months?
Cronos Group lowest stock price was C$3.23 and its highest was C$4.99 in the past 12 months.
What is Cronos Group’s market cap?
Cronos Group’s market cap is C$1.68B.
When is Cronos Group’s upcoming earnings report date?
Cronos Group’s upcoming earnings report date is Nov 11, 2026 which is in 39 days.
How were Cronos Group’s earnings last quarter?
Cronos Group released its earnings results on Aug 06, 2026. The company reported C$0.128 earnings per share for the quarter, beating the consensus estimate of C$0.014 by C$0.114.
Is Cronos Group overvalued?
According to Wall Street analysts Cronos Group’s price is currently Undervalued.
Does Cronos Group pay dividends?
Cronos Group does not currently pay dividends.
What is Cronos Group’s EPS estimate?
Cronos Group’s EPS estimate is 0.04.
How many shares outstanding does Cronos Group have?
Cronos Group has 368,412,870 shares outstanding.
What happened to Cronos Group’s price movement after its last earnings report?
Cronos Group reported an EPS of C$0.128 in its last earnings report, beating expectations of C$0.014. Following the earnings report the stock price went up 13.684%.
Which hedge fund is a major shareholder of Cronos Group?
Currently, no hedge funds are holding shares in TSE:CRON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cronos Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$7.00 (41.41% Upside)
C$7.00 (41.41% Upside)
Blogger Sentiment
Bullish
TSE:CRON Sentiment 86%
Sector Average 65%
Sector Average 65%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cronos Group
Cronos Group Inc. functions as a diversified global cannabinoid enterprise. Within the United States, it manufactures, promotes, and distributes a variety of hemp-derived supplements and cosmetic products. These items are available under its Lord Jones and Happy Dance brands through online sales, traditional retail, and hospitality partner networks. The company also plays a significant role in the cultivation, production, and commercialization of cannabis and cannabis-infused products for both medicinal and adult-use sectors. Its comprehensive product offerings encompass dried cannabis flower, pre-rolled joints, edibles, concentrated forms, and cannabis extracts. These are distributed via wholesale partnerships and direct-to-consumer channels, prominently featuring its wellness platform, PEACE NATURALS, and its adult-use brand, Spinach. Moreover, Cronos Group exports dried cannabis and cannabis oils to international markets including Germany, Israel, and Australia. Established in 2012, the company maintains its corporate headquarters in Toronto, Canada.
CRON Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and financial picture: record revenue, gross profit, and adjusted EBITDA, strong brand performance (notably Spinach), meaningful international growth (Israel and Germany), and a robust cash position. Key risks and headwinds include a new anti-dumping investigation in Israel, modest OpEx increases, margin variability tied to seasonality and mix, and timing uncertainty around the CanAdelaar closing. On balance, the positive operational momentum and strong financials outweigh the highlighted risks.View all TSE:CRON earnings summariesCRON Stock 12 Month Forecast
Average Price Target
C$7.00
▲(41.41% Upside)